2023 Fiscal Year Final Research Report
Development of specific therapeutic agents for intractable pruritus without side effects
| Project/Area Number |
21K06602
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 47040:Pharmacology-related
|
|---|
| Research Institution | Tohoku Medical and Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
渡辺 千寿子 東北医科薬科大学, 薬学部, 准教授 (90296020)
|
|---|
| Project Period (FY) |
2021-04-01 – 2024-03-31
|
| Keywords | 難治性掻痒 / μオピオイド受容体 / 末梢性作用 |
|---|
| Outline of Final Research Achievements |
This research found that not only KOR agonists but also MOR agonists exerted strong antipruritic effects when administered transdermally in various pathological pruritus experimental animal models (dry skin pruritus, contact dermatitis pruritus, 5-HT-induced pruritus, and deoxycholic acid-induced pruritus). There is discrepancy in the effectiveness of some MOR agonists against the pruritus models, and it is suggested that various MOR splice variants may be involved in these differences.
|
| Free Research Field |
疼痛・掻痒制御
|
| Academic Significance and Societal Importance of the Research Achievements |
難治性病態性掻痒の治療薬は、現在KOR作動薬のナルフラフィンしか存在せず、新たな治療薬の開発が望まれている。本研究課題の成果によって、従来掻痒誘発に働くと考えられていたMOR作動薬も、経皮投与によって病態性掻痒に対し強力な抗掻痒作用を示すことが明らかとなり、難治性病態掻痒に対する新規治療薬のターゲットが追加された。ターゲットとなりうるMORのスプライスバリアントを解明することにより、副作用の無い難治性病態掻痒治療薬の開発に繋がると考えられる。
|
